Product Description: Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Qing Z, et, al. Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma. Journal of Clinical Oncology. 2017;35 (7_suppl):108-108.
CAS Number: 2348469-43-0
Molecular Weight: N/A
Compound Purity: 97.72
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: PD-1/PD-L1